Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06671405 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions
A Phase 1 study of Dyslipidaemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT06671405: Completed Phase 1 study of Dyslipidaemia, sponsored by AstraZeneca.
NCT06671405 is a Phase 1 study of Dyslipidaemia that has completed, run by AstraZeneca. The registered enrollment target is 59 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06671405, a Phase 1 study of Dyslipidaemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
An open-label, fixed sequence study in healthy participants to assess the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine, and to assess the pharmacokinetics of midazolam and ethinyl estradiol/levonorgestrel (EE and LNG) when administered alone and in combination with AZD0780.
Primary Outcome
To describe the PK of AZD0780 when administered alone and in combination with itraconazole and carbamazepine.
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Itraconazole
- DRUG AZD0780
- DRUG Carbamazepine
- DRUG Ethinyl estradiol/levonorgestrel
Study Locations (1)
Maryland
- Research Site - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2025-02-17 |
| Phase | Phase 1 |
What the finished NCT06671405 record still lists
NCT06671405 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Dyslipidaemia appearing as the primary indexed condition, and to 5 interventions - of which Midazolam is the first listed.
NCT06671405 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06671405 about?
NCT06671405 is a clinical study titled "An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions". An open-label, fixed sequence study in healthy participants to assess the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine, and to assess the pharmacokinetics of midazolam and ethinyl estradiol/levonorgestrel (EE and LNG) when administered al...
What is the current status of trial NCT06671405?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2024-09-25. Estimated completion is 2025-02-17.
What conditions does trial NCT06671405 study?
This clinical trial studies the following conditions: Dyslipidaemia.
What interventions are being tested in trial NCT06671405?
The interventions under investigation include: Midazolam (DRUG), Itraconazole (DRUG), AZD0780 (DRUG), Carbamazepine (DRUG), Ethinyl estradiol/levonorgestrel (DRUG).
Who is sponsoring clinical trial NCT06671405?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06671405 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06671405's enrollment target sits among peer trials
59 895th of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI